1. [Combination chemotherapy with oral TS-1 and low-dose CPT-11 by hepatic arterial infusion for multiple hepatic metastases from colon cancer--a case report].
- Author
-
Hiraki M, Yakushiji H, Hashiguchi K, and Harada S
- Subjects
- Administration, Oral, Ambulatory Care, Camptothecin administration & dosage, Colonic Neoplasms pathology, Colonic Neoplasms surgery, Combined Modality Therapy, Drug Administration Schedule, Drug Combinations, Hepatic Artery, Humans, Infusion Pumps, Implantable, Infusions, Intra-Arterial, Irinotecan, Male, Middle Aged, Oxonic Acid administration & dosage, Pyridines administration & dosage, Tegafur administration & dosage, Adenocarcinoma drug therapy, Adenocarcinoma secondary, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin analogs & derivatives, Colonic Neoplasms drug therapy, Liver Neoplasms drug therapy, Liver Neoplasms secondary
- Abstract
Combined chemotherapy consisting of oral TS-1 and low-dose CPT-11 by hepatic arterial infusion is suggested to be a new effective treatment for multiple liver metastases from colorectal cancer. A 53-year-old man was diagnosed with multiple hepatic metastases from advanced colon cancer (Stage IV). The patient underwent partial resection of the colon and catheter insertion into hepatic artery for arterial infusion in November 2003. He was treated with postoperative combination chemotherapy consisting of UFT and low-dose CPT-11. UFT was administered orally at 400 mg/body/day everyday and CPT-11 was injected at 40 mg/body/week for 6 weeks, followed by a 2 weeks rest interval as 1 cycle. In spite of the reduction of metastatic liver tumors after 2 cycles of the chemotherapy, a metastatic pleural tumor appeared. Therefore, we judged the effect of the chemotherapy to be a progressive disease and changed UFT in the regimen to TS-1. TS-1 was administered orally at 80 mg/body/day under a 2-weeks-on and 1-week-off regimen for 3 times. CPT-11 was injected at 40 mg/body/week for 6 weeks, followed by a 3 weeks rest interval as 1 cycle. A stable disease was maintained for 3 months. Outpatient care was possible because no severe events were observed. Tumors showed a reduction rate of 37.4% after the combination therapy. The patient survived for 285 days after the operation.
- Published
- 2005